Becker Transactions puts 20-plus non-opioid pain patents up for sale

Becker Transactions is offering for sale a patent portfolio of more than 20 assets from 3V Medical Research Group covering copper-ion-based approaches for pain, infections and skin care. The deal could interest drug, consumer health and medical product companies looking for non-opioid treatment options and copper-ion products.

Why it matters: - The portfolio targets pain relief without opioids, a major advantage as companies look for alternatives to opioid-based medications. - The patents also extend into infection treatment and skin care, broadening the commercial uses beyond pain management. - The offering could be relevant to pharmaceutical companies, consumer healthcare brands and medical product manufacturers building copper-ion-based products.

What happened: - Becker Transactions announced it is offering for sale more than 20 patents developed by 3V Medical Research Group. - The portfolio covers copper-ion-based solutions for treating pain, viruses, bacteria and fungi, plus methods for generating copper ions used to form copper ion peptides for skin care. - The patents were built over more than a decade of research and development with millions invested.

The details: - The portfolio includes base compositions and suspensions identified in conducted studies as 3VM1000. - The portfolio includes base compositions and suspensions in cream form identified in conducted studies as 3VM1001. - The portfolio covers additional delivery formats, including gels, foams and transdermal patches. - The portfolio includes manufacturing methods for the compositions, suspensions and delivery systems. - The portfolio includes methods for treating specified pain, viral, bacterial, fungal and dermatological conditions. - For pain management, the portfolio covers cream and transdermal patch approaches for delivering a low concentration of soluble copper. - The delivery methods are designed to keep copper intake below recommended daily allowance levels. - The approach is intended to avoid toxicity risks tied to gastrointestinal and liver exposure from oral or injected medications. - Potential applications include chronic osteoarthritis pain, radiation dermatitis, shingles and post-herpetic neuralgia. - The U.S. market opportunity is estimated at about $3.5 billion annually for knee-pain treatment alone. - The U.S. market opportunity is estimated at more than $210 million annually for radiation dermatitis across cancer-treatment applications. - The U.S. market opportunity is estimated at about $200 million annually for shingles and post-herpetic neuralgia. - The U.S. market opportunity is estimated at more than $100 million annually for copper ion peptide skin care applications.

Between the lines: - The patent package is positioned as both a therapeutic and consumer-facing asset, which could widen the buyer pool. - Dean Becker, chairman of Becker Transactions, said the portfolio offers strategic value to companies seeking intellectual property in copper-ion-based healthcare and consumer products. - The emphasis on delivery formats and manufacturing methods suggests the portfolio is meant to support product development, not just basic composition claims.

What's next: - Becker Transactions is seeking licensing or acquisition deals for the portfolio. - Olivia N Becker is the contact for additional information, at Becker Transactions, +1 662-338-6617. - The portfolio may draw interest from companies developing copper-ion-based treatments or skin care products.